PRP vs GFC Hair Therapy

Platelet-rich plasma (PRP) is a supportive therapy in which a small volume of the patient's own blood is drawn, processed in a centrifuge to concentrate platelets, and injected at the scalp. The framework is biological — platelets release growth factors that may support follicular activity in suitable candidates. PRP is offered as an adjunctive supportive therapy alongside dermatology-led hair-loss management; it is not a stand-alone hair-regrowth solution and outcomes vary substantially between patients. The clinic positions PRP as supportive rather than as a fixed-outcome regrowth solution.

Growth factor concentrate (GFC) is a related supportive therapy that uses platelet-derived growth factors processed in a way intended to deliver the active components without some of the cellular elements of conventional PRP. The clinical rationale and supportive framework are similar to PRP. GFC is offered as adjunctive supportive therapy at clinics that use the technique; the framework is the same — supportive, not stand-alone, with variable individual outcomes. The clinic does not present GFC as superior to PRP or as an absolute solution.

Honest framing: the clinical evidence comparing PRP and GFC for hair concerns is not definitive enough to support a universal verdict that one is meaningfully more effective than the other for all patients. Both are positioned as supportive therapies with reasonable safety profiles in trained hands; both have variable individual response; both are part of a broader hair-loss framework rather than stand-alone solutions. The clinic does not promote either as superior. Selection at consultation considers individual factors including cause of hair loss, severity, response to other interventions, and patient preference.

No. Supportive therapies like PRP and GFC are typically considered for early-to-moderate androgenetic alopecia (pattern hair loss) where some follicular activity remains. They are less likely to provide meaningful effect for advanced loss with substantial follicular dropout, scarring alopecia (where follicles are destroyed by inflammation), end-stage pattern loss, or hair loss from active medical conditions warranting medical management first. The dermatology consultation evaluates suitability rather than offering supportive therapy universally. The hair fall guide covers the broader assessment framework.

Realistic expectations: most protocols involve a course of three-to-six sessions spaced four-to-six weeks apart for the initial phase, with maintenance sessions every four-to-six months for sustained support. The framework is sustained supportive therapy alongside other interventions rather than single-session transformation. Patients seeking single-session results are typically disappointed. The dermatology consultation provides individualised session-count guidance.

Both involve scalp injections at multiple points across the affected zone and produce a brief sharp sensation per injection. Topical numbing or local anaesthetic delivery can support tolerability. Most patients tolerate the sessions adequately; the clinic does not present either as completely sensation-free. Honest discussion at consultation matters.

Both therapies carry honest considerations. Common transient effects — mild scalp tenderness, redness, and minor swelling resolving over days. Bruising at injection sites in some patients. Risk of infection as with any injection-based procedure, very low with appropriate sterile technique. Headache in some patients post-session. Variable individual response — some patients see meaningful change, others see less. The framework: experienced delivery at calibrated technique by appropriately trained operators carries reasonable safety; non-medical settings carry meaningful risks. The clinic does not present either as side-effect-free.

Indian and broader Fitzpatrick III–VI skin reacts more readily with post-inflammatory hyperpigmentation in response to procedural intervention. Scalp injections themselves carry low pigmentation risk because the scalp is largely hair-bearing rather than skin-visible. Periorbital or temple zones near visible skin warrant gentle technique. The framework: both PRP and GFC are reasonable for Indian-skin patients with appropriate technique. The Indian Skin Treatment Safety Guide covers the broader framework.

Yes — combination is the typical framework rather than the exception. Most patients pursuing supportive injectable therapy continue topical interventions (minoxidil where appropriate), oral interventions where indicated, dermatology-led scalp care, and broader lifestyle support. The framework: supportive therapy sits within a broader hair-loss management plan. The dermatology consultation shapes the integrated framework rather than presenting injectable therapy as the sole intervention.

Both have similar safety profiles in experienced hands. PRP uses the patient's own blood with minimal processing; GFC uses processed concentrate. Both are typically positioned as well-tolerated when delivered with appropriate technique. The framework: safety differences between the two are not the dominant consideration; selection considers individual case factors and clinic protocols rather than categorical safety preference. The clinic does not promote one as inherently safer than the other.

Realistic expectations: response varies substantially between patients. Some patients see meaningful supportive effect that persists with sustained maintenance sessions; some see modest response; some see limited response. The framework is sustained therapy alongside other interventions rather than one-off treatment. Patients abandoning therapy often see the supportive effect diminish over months. Honest discussion of variable outcomes is part of the consultation.

Honest framing: supportive therapies aim to support existing follicular activity in suitable candidates; they may help with thickness, density, and reduced shedding in some patients. They do not reliably regenerate follicles that have been lost or restore advanced patterns of loss. Patients with substantial loss typically benefit from broader assessment including dermatology consultation, evaluation of medical interventions, and discussion of surgical options where appropriate. The clinic does not promise regrowth.

Reasonable triggers include: persistent or progressive hair loss warranting characterisation; planning supportive therapy; questions about candidacy; integrated assessment alongside scalp conditions or systemic features (thyroid, nutritional, hormonal); or simply the patient's decision to discuss the framework with informed evaluation. The dermatologist consultation can shape the regimen and recommend appropriate intervention. The hair fall guide and early hair loss intervention guide cover broader frameworks.